AcelRx Pharmaceuticals of Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Pharmacosmos Therapeutics Inc. was established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric for iron deficiency anemia (IDA) patients in the United States.
Raj Kannan was appointed CEO of Chiasma Inc.
Tumble blender technology enhances the speed and homogeneous blending of tablets and capsules with trace levels of additives To meet stringent regulatory requirements, such as the United States […]
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
The U.S. FDA accepted for review Foamix Pharmaceuticals Ltd.’s New Drug Application (NDA) for FMX101 for treating inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.
SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activating people with rare disorders.
Jacob Chacko, M.D., is now CEO of ORIC Pharmaceuticals. Rich Heyman, Ph.D., who served as the interim CEO, became chairman of the ORIC board of directors. The former chairman, Peter Svennilson, remains on the board.
Endo International plc announced that it has reached definitive agreements to acquire Somerset Therapeutics LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India-based affiliate Wintac Limited, which operates as Somerset Therapeutics’ contract developer and manufacturer.
Karen Reeves, M.D., was appointed by AZTherapies as president and chief medical officer.
